IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising
two phases: dose confirmation phase and dose expansion phase. The objective of the dose
confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard
chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard
chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will
further explore the antitumor activities and safety of combination therapy in subjects with
advanced pancreatic cancer.